Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics

Journal of Controlled Release

Volumn 145, Issue 1, 2010, Pages 9-16

  Hirata, Kenshiro ^a   Maruyama, Toru ^a   Watanabe, Hiroshi ^a   Maeda, Hitoshi ^a   Nakajou, Keisuke ^b   Iwao, Yasunori ^a   Ishima, Yu ^a   Katsumi, Hidemasa ^c,d   Hashida, Mitsuru ^c   Otagiri, Masaki ^a,e  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Nipro Corporation   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^e SOJO UNIVERSITY   (Japan)

Author keywords

Human serum albumin; Ischemia reperfusion; Mannosylation; Nitric oxide; Recombinant albumin

Indexed keywords

BLOOD CIRCULATION; CHEMICALLY MODIFIED; DRUG DELIVERY SYSTEM; GLYCOSYLATED; HEME OXYGENASE-1; HUMAN SERUM ALBUMINS; IN-VIVO; INHIBITORY EFFECT; INJURY MODELS; ISCHEMIA REPERFUSION; KUPFFER CELLS; MANNOSE RECEPTORS; PARENCHYMAL CELLS; PHARMACOKINETIC ANALYSIS; TRIPLE MUTANTS;

BODY FLUIDS; CARDIOVASCULAR SYSTEM; DRUG DELIVERY; GENETIC ENGINEERING; NITRIC OXIDE; PORPHYRINS;

LIVER;

HEME OXYGENASE 1; HUMAN SERUM ALBUMIN; MANNOSE RECEPTOR; NITRIC OXIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENETIC VARIABILITY; GLYCOSYLATION; IMMUNOGENICITY; KUPFFER CELL; MANNOSYLATION; MOUSE; NITROSYLATION; NONHUMAN; OSMOTIC PRESSURE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PURIFICATION; RAT; SITE DIRECTED MUTAGENESIS; TISSUE DISTRIBUTION;

ANIMALS; BLOTTING, WESTERN; CIRCULAR DICHROISM; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIAL CELLS; HEME OXYGENASE-1; HUMANS; KUPFFER CELLS; LECTINS, C-TYPE; LIVER; MANNOSE; MANNOSE-BINDING LECTINS; MICE; MICE, INBRED STRAINS; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; REPERFUSION INJURY; SERUM ALBUMIN; TISSUE DISTRIBUTION;

EID: 77953359431     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.03.010     Document Type: Article

References (27)

1. Chuang V.T., Kragh-Hansen U., Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 2002, 19:569-577.
2. Minchiotti L., Campagnoli M., Rossi A., Cosulich M.E., Monti M., Pucci P., Kragh-Hansen U., Granel B., Disdier P., Weiller P.J., Galliano M. A nucleotide insertion and frameshift cause albumin Kenitra, an extended and O-glycosylated mutant of human serum albumin with two additional disulfide bridges. Eur. J. Biochem. 2001, 268:344-352.
3. Brennan S.O., Myles T., Peach R.J., Donaldson D., George P.M. Albumin Redhill (-1 Arg, 320 Ala--Thr): a glycoprotein variant of human serum albumin whose precursor has an aberrant signal peptidase cleavage site. Proc. Natl Acad. Sci. USA 1990, 87:26-30.
4. Carlson J., Sakamoto Y., Laurell C.B., Madison J., Watkins S., Putnam F.W. Alloalbuminemia in Sweden: structural study and phenotypic distribution of nine albumin variants. Proc. Natl Acad. Sci. USA 1992, 89:8225-8229.
5. Peach R.J., Brennan S.O. Structural characterization of a glycoprotein variant of human serum albumin: albumin Casebrook (494 Asp--Asn). Biochim. Biophys. Acta 1991, 1097:49-54.
6. Gemmill T.R., Trimble R.B. Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochim. Biophys. Acta 1999, 1426:227-237.
7. Higuchi Y., Nishikawa M., Kawakami S., Yamashita F., Hashida M. Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. Int. J. Pharm. 2004, 287:147-154.
8. Yabe Y., Nishikawa M., Tamada A., Takakura Y., Hashida M. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. J. Pharmacol. Exp. Ther. 1999, 289:1176-1184.
9. Kuo Y.R., Wang F.S., Jeng S.F., Lutz B.S., Huang H.C., Yang K.D. Nitrosoglutathione promotes flap survival via suppression of reperfusion injury-induced superoxide and inducible nitric oxide synthase induction. J. Trauma 2004, 57:1025-1031.
10. Ishima Y., Sawa T., Kragh-Hansen U., Miyamoto Y., Matsushita S., Akaike T., Otagiri M. S-Nitrosylation of human variant albumin Liprizzi (R410C) confers potent antibacterial and cytoprotective properties. J. Pharmacol. Exp. Ther. 2007, 320:969-977.
11. Ikebe N., Akaike T., Miyamoto Y., Hayashida K., Yoshitake J., Ogawa M., Maeda H. Protective effect of S-nitrosylated alpha(1)-protease inhibitor on hepatic ischemia-reperfusion injury. J. Pharmacol. Exp. Ther. 2000, 295:904-911.
12. Matsushita S., Isima Y., Chuang V.T., Watanabe H., Tanase S., Maruyama T., Otagiri M. Functional analysis of recombinant human serum albumin domains for pharmaceutical applications. Pharm. Res. 2004, 21:1924-1932.
13. Yabe Y., Kobayashi N., Nishikawa M., Mihara K., Yamashita F., Takakura Y., Hashida M. Pharmacokinetics and preventive effects of targeted catalase derivatives on hydrogen peroxide-induced injury in perfused rat liver. Pharm. Res. 2002, 19(12):1815-1821.
14. Scott T.A., Melvin E.H. The determination of dextran with anthrone. Anal. Chem. 1953, 25:1656-1661.
15. Hnatowich D.J., Layne W.W., Childs R.L. The preparation and labeling of DTPA-coupled albumin. Int. J. Appl. Radiat. Isot. 1982, 33(5):327-332.
16. Matsushita S., Chuang V.T., Kanazawa M., Tanase S., Kawai K., Maruyama T., Suenaga A., Otagiri M. Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin. Pharm. Res. 2006, 23(5):882-891.
17. Tabuchi M., Umegaki K., Ito T., Suzuki M., Tomita I., Ikeda M., Tomita T. Fluctuation of serum NO(x) concentration at stroke onset in a rat spontaneous stroke model (M-SHRSP). Peroxynitrite formation in brain lesions. Brain Res. 2002, 949:147-156.
18. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 1981, 4(11):879-885.
19. Murata M., Tamai I., Sai Y., Nagata O., Kato H., Sugiyama Y., Tsuji A. Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. Drug Metab. Dispos. 1998, 26(11):1113-1119.
20. Blanchard V., Gadkari R.A., Gerwig G.J., Leeflang B.R., Dighe R.R., Kamerling J.P. Characterization of the N-linked oligosaccharides from human chorionic gonadotropin expressed in the methylotrophic yeast Pichia pastoris. Glycoconj. J. 2007, 24:33-47.
21. Opanasopit P., Sakai M., Nishikawa M., Kawakami S., Yamashita F., Hashida M. Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. J. Control. Release 2002, 80:283-294.
22. Bouton C., Demple B. Nitric oxide-inducible expression of heme oxygenase-1 in human cells. Translation-independent stabilization of the mRNA and evidence for direct action of nitric oxide. J. Biol. Chem. 2000, 275(42):32688-32693.
23. Jones S.P., Greer J.J., Kakkar A.K., Ware P.D., Turnage R.H., Hicks M., van Haperen R., de Crom R., Kawashima S., Yokoyama M., Lefer D.J. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2004, 286(1):H276-H282.
24. Pabla R., Buda A.J., Flynn D.M., Salzberg D.B., Lefer D.J. Intracoronary nitric oxide improves postischemic coronary blood flow and myocardial contractile function. Am. J. Physiol. 1995, 269(3Pt 2):H1113-H1121.
25. Devey L., Ferenbach D., Mohr E., Sangster K., Bellamy C.O., Hughes J., Wigmore S.J. Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. Mol. Ther. 2009, 17(1):65-72.
26. Broide E., Klinowski E., Koukoulis G., Hadzic N., Portmann B., Baker A., Scapa E., Mieli-Vergani G. Superoxide dismutase activity in children with chronic liver diseases. J. Hepatol. 2000, 32(2):188-192.
27. Serracino-Inglott F., Habib N.A., Mathie R.T. Hepatic ischemia-reperfusion injury. Am. J. Surg. 2001, 181(2):160-166.